Removal of Generic Litigation Overhang Could Push Amarin (AMRN) to $25-30 - Jefferies
Tweet Send to a Friend
Jefferies analyst Michael Yee provided his takeaways from a recent call with a patent lawyer related to ongoing generics litigation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


